Wall Street analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to report ($0.03) earnings per share (EPS) for the current quarter, Zacks reports. Six analysts have made estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from ($0.23) to $0.23. Collegium Pharmaceutical reported earnings of ($0.10) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 70%. The firm is expected to issue its next earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.52) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.15). For the next year, analysts forecast that the business will post earnings of $0.20 per share, with EPS estimates ranging from ($0.57) to $0.94. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The business had revenue of $72.94 million for the quarter, compared to analyst estimates of $74.32 million. During the same quarter last year, the company earned ($0.50) EPS. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year.
Several research analysts have commented on COLL shares. Needham & Company LLC lowered their target price on Collegium Pharmaceutical from $33.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 30th. SunTrust Banks boosted their target price on Collegium Pharmaceutical to $22.00 and gave the stock a “buy” rating in a research note on Friday. Jefferies Financial Group boosted their target price on Collegium Pharmaceutical from $26.00 to $36.00 in a research note on Thursday. ValuEngine raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, William Blair reissued a “buy” rating on shares of Collegium Pharmaceutical in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $24.57.
Shares of COLL traded up $1.96 during mid-day trading on Friday, hitting $19.96. 1,220,900 shares of the company’s stock were exchanged, compared to its average volume of 378,932. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 0.23. The stock has a market cap of $459.95 million, a price-to-earnings ratio of -16.77 and a beta of 0.52. Collegium Pharmaceutical has a twelve month low of $10.01 and a twelve month high of $19.99. The firm has a fifty day moving average of $12.16 and a two-hundred day moving average of $12.08.
In other news, CEO Joseph Ciaffoni sold 64,821 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $18.77, for a total value of $1,216,690.17. Following the completion of the transaction, the chief executive officer now owns 242,276 shares of the company’s stock, valued at $4,547,520.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Hirsch sold 22,106 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $11.65, for a total value of $257,534.90. Following the completion of the transaction, the director now directly owns 64,223 shares of the company’s stock, valued at approximately $748,197.95. The disclosure for this sale can be found here. Corporate insiders own 8.08% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in COLL. Janus Henderson Group PLC increased its position in Collegium Pharmaceutical by 19.1% during the 2nd quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after purchasing an additional 693,812 shares during the period. Renaissance Technologies LLC acquired a new stake in Collegium Pharmaceutical during the 2nd quarter valued at approximately $3,210,000. Cortina Asset Management LLC increased its position in Collegium Pharmaceutical by 81.0% during the 2nd quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock valued at $6,703,000 after purchasing an additional 228,035 shares during the period. Nuveen Asset Management LLC acquired a new stake in Collegium Pharmaceutical during the 2nd quarter valued at approximately $2,622,000. Finally, BlackRock Inc. increased its position in Collegium Pharmaceutical by 7.1% during the 2nd quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock valued at $32,724,000 after purchasing an additional 165,018 shares during the period. 92.17% of the stock is owned by institutional investors.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Recommended Story: Trade War
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.